Ultrasound Therapeutic System

HAIFU ® Model-JC Therapeutic System

Haifu® Model JC is a unique therapeutic system for non-invasive extracorporeal  treatment of benign (not cancerous)   and malignant (cancerous) tumors through the use of High-Intensity Focused Ultrasound (HIFU), which  is not only the first of its kind in the world but the first CE marked extracorporeal therapeutic system for malignant- tumor - treatment in the world.

How does it work?


HAIFU ® Model-JC has its own computer software to merge CT (MRI) imaging with ultrasound images. This ensures maximum precision for the doctor and security and safety for the patient. 
HAIFU ® Model-JC integrates optimized planning, real-time image guidance and high-intensity focused ultrasound (HIFU) energy deposition in the target zone of the tumor. The power can reach 25,000 W/cm² in the focused area, which increases the temperature there (> 60°C) to cause tumor necrosis (death of the tumor cells) without affecting any of the surrounding tissue.

HAIFU ® Model-JC is the ultrasound guided therapeutic system which allows the physician to adjust the orientation, position and intensity of the ultrasound beam in real time according to the observed image of the target area.
The target area with tissue cells that have to be destroyed can be as small as 1,1 mm x 3,3 mm. The precise linear motion system (deviation: ± 1 mm) ensures that only and exactly this area will be treated. The system provides the physician with a very precise "invisible knife” – the ultrasound. It ablates tumors while preserving healthy tissue.

In most malignant tumors, though, 10-15 mm of the surrounding healthy tissue has to be ablated in order to obtain a complete and secure ablation with a radical resective line of  the tumor.

HIFU can treat benign (not cancerous) tumors:What kinds of tumors can be treated with HAIFU ® Model-JC Therapeutic System?

  • Uterine fibroids (myoma)

  • Breast Fibroadenoma

  • Adenomiosis (uterine disease)

HIFU can complement the standard treatment of malignant solid (cancerous) tumors of:

  • Pancreas

  • Liver – HCC (Hepatocellular Carcinoma) and  Liver metastases

  • Breast

  • Soft tissues

  • Kidney

HIFU can be used as:

  • a pain relief palliative treatment of advanced malignancy

  • as a treatment of tumors in difficult for conventional surgery position

  • as a treatment of recurrent tumors after conventional surgery





SEAPOSTAR ® MODEL – CZF HIFU device is used for non-invasive treatment  of some of the  most frequent gynecological diseases  of the UTERINE CERVIX and the VULVA.

SEAPOSTAR ® MODEL – CZF provides an organ-sparing and harmless clinical approach that replaces the conventional surgical treatment.

INDICATIONS (diseases):

  • Symptomatic ectopia of the uterine cervix
  • Cervicitis (inflammation of the uterine cervix)
  • HPV-infection
  • Non-neoplastic intraepithelial lesions of the vulva (vulvar dystrophies):
  • Lichen sclerosus
  • Squamous cell hyperplasia
  • Vulval condyloma acuminatum


  • A completely non-invasive method - no surgical excisions, scars and other changes on  the skin and the mucosa - high-intensity focused ultrasound (HIFU) penetrates deeply but the skin and  mucosa are absolutely intact and preserved.
  • an organ-sparing procedure - femininity is spared, self-confidence and quality of life are significantly improved
  • Efficiency – after the treatment of the diseases by the- high intensity focused ultrasound (HIFU) no recurrences are observed.
  • Accuracy - HIFU eliminates only and precisely the tumor cells in the body, without affecting the surrounding tissues and the normal functions of the body
  • Monitoring the impact of treatment in real time
  • Absolutely safe and harmless method


  • The focal length is short and easy for manipulation
  • It is suitable for various treatment targets, because the components are flexible and the parameters are adjustable
  • Monitoring is in real time
  • Targeting is non-invasive and accurate
  • Optimized clinical protocols and standards are used

N.B.  According to the medical records, the symptoms are improved in 95% of the cases treated by SEAPOSTAR ® MODEL-CZF